TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana : key facts

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Daily oral PrEP with a tablet containing tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known by the brand name Truvada®) was found to reduce the risk of acquiring HIV infection by roughly 63 percent in the study population overall.
  
  In addition, researchers conducted a separate analysis to better understand the level of efficacy among trial participants believed to be taking study medications. This analysis excludes any HIV infections that occurred more than 30 days1 after a participant’s last reported drug dose, because those individuals could not have been taking study pills at the time of infection. These results indicate that TDF/FTC reduced the risk of HIV infection by 78 percent.
  
  
• Subjects:
  Anti-HIV Agents/therapeutic Use HIV Infections/prevention & Control Organophosphonates/therapeutic Use Truvada
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Fact Sheet
• Place as Subject:
  Botswana
• Pages in Document:
  4 numbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:630506d34843409abb135d02ad0442f7caa3d500903de81c6044c06ccf5170e6
• Download URL:
  https://stacks.cdc.gov/view/cdc/23283/cdc_23283_DS1.pdf
• File Type:
  [PDF - 98.02 KB ]